A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2201-2208

  McDermott, David F ^a   Mier, James W ^a   Lawrence, Donald P ^a   Van Den Brink, Marcel R M ^a   Clancy, Marquerite A ^a   Rubin, Krista M ^a   Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DACARBAZINE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYZINE; LORAZEPAM; ONDANSETRON; PARACETAMOL; PETHIDINE; RANITIDINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; VINBLASTINE;

ADULT; AGED; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CATHETER INFECTION; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOTENSION; KIDNEY FAILURE; MALE; MELANOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RIGOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0034043168     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Atkins, M. B. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: J. M. Kirkwood (ed.), Molecular Diagnosis, Prevention and Therapy of Melanoma, pp. 219-251. New York: Marcel Dekker, Inc. 1998.
2. Albino, A. P., Redd, J. A., and McNutt, N. S. Malignant Melanoma. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 1935-1994. Philadelphia: Lippincott and Raven Publishers, 1997.
3. Houghton, A. N., Legha, S., and Bajorin, D. F. Chemotherapy for Metastatic Melanoma. In: C. M. Balch, A. N. Houghton, S. G. Milton, A. J. Sober, and S. Soong (eds.), Cutaneous Melanoma, Ed. 2, pp. 498-508. Philadelphia: J. B. Lippincott Company, 1992.
4. DelPrete, S. A., Maurer, L. H., and O'Donnell, J. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat. Rep., 69: 1403-1411, 1984.
5. Buzaid, A. C., Legha, S., Winn, R., Belt, R., Pollock, T., Wiseman, C., and Ensign, L. G. Cisplatin, vinblastine, and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: preliminary results of a Phase II cancer community oncology program (CCOP) trial. Proc. Am. Soc. Clin. Oncol., 12: 389, 1993.
6. Saxman, S. B., Meyers, M. L., Chapman, P. B., Destro, A. N., Panageas, K. S., Begg, C. B., Monaco, F., Agarwala, S. S., Schucter, L. M., Ernstoff, M. S., Einhorn, L. H., Kirkwood, J. M., and Houghton, A. N. A Phase II multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. Proc. Am. Soc. Clin. Oncol., 18: 536, 1999.
7. Rhusthoven, J. J., Quirt, I. C., Iscoe, N. A. McCulloch, P. B., James, K. W., Lohmann, R. C., Jensen, J., Burdette-Radoux, S., Bodurtha, A. J., Silver, H. K., Verma, S., Armitage, G. R., Zee, B., and Bennett, K. Randomized, double-blind placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 14: 2083-2090, 1986.
8. Falkson, C. I., Ibrahim, J., Kirkwood, J., Coates, A. S., Atkins, M. B., and Blum, R. Phase III trial of dacarbazine versus dacarbazine with interferon 2b versus dacarbazine with tamoxifen versus dacarbazine with interferon 2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study (E3690). J. Clin. Oncol., 16: 1743-1751, 1998.
9. Kirkwood, J. M. Studies of interferon in the therapy of melanoma. Semin. Oncol., 18 (Suppl. 7): 83-89, 1991.
10. Sparano, J. A., and Dutcher, J. P. Interleukin-2 for the treatment of advanced melanoma. Hematol. Oncol. Ann., 1: 279-285, 1993.
11. Atkins, M. B., Lotze, M., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., and Rosenberg, S. A. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated from 1985-1993. J. Clin. Oncol., 17: 2105-2116, 1999.
12. Sparano, J. A., Fisher, R. I., Sunderland, M., Margolin, K., Ernest, M. L., Sznol, M., Atkins, M. B., Dutcher, J. P., Micetich, K. C., and Weiss, G. R. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon α-2a in patients with advanced melanoma. J. Clin. Oncol., 11: 1969-1977, 1993.
13. Richards, J. M., Gale, D., Mehta, N., and Lestingi, T. Combination of chemotherapy with interleukin-2 and interferon a for the treatment of metastatic melanoma. J. Clin. Oncol., 17: 651-657, 1999.
14. Legha, S. S., and Buzaid, A. C. Role of recombinant interleukin-2 in combination with interferon-a and chemotherapy in the treatment of advanced melanoma. Semin. Oncol., 2 (Suppl. 9): 27-32, 1993.
15. Atkins, M. B., O'Boyle, K. R., Sosman, J. A., Weiss, G. R., Margolin, K. A., Ernest, M. L., Mier, J. W., Sparano, J. A., and Fisher, R. I. Multi-institutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol., 12: 1553-1560, 1994.
16. Khayat, D., Borel, C., Tourani, J. M., Benhammouda, A., Antoine, E., Rixe, O., Viullemin, E., Bazex, P. A., Thill, L., and Franks, R. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon α-2a for metastatic melanoma. J. Clin. Oncol., 12: 2173-2180, 1993.
17. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Buzaid, A. C., Plager, C., and Papadopoulos, N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon α and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol., 16: 1752-1759, 1998.
18. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
19. Parkinson, D. R. Interleukin-2 in cancer therapy. Semin. Oncol., 15 (Suppl. 6): 10-26, 1988.
20. Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., and Roper, M. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol., 7: 486-498, 1989.
21. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696, 1995.
22. Mitchell, M. S. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J. Clin. Oncol., 7: 1701-1709, 1989.
23. Summers, Y., Middleton, M. R., Calvert, H., Lee, S. M., Rustin, G., Newell, D. R., and Thatcher N. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol., 18: 2048, 1999.
24. Bleehen, N. M., Newlands, S. M., Lee, S. M., Thatcher, L. N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., and Stevens, M. F. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
25. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., and Steinberg, S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon α-2b. J. Clin. Oncol., 17: 968-975, 1999.
26. Keilholz, U., Goey, S. H., Punt, C. J., Proebstle, T. M., Salzmann, R., Scheibenbogen, C., Schadendorf, D., Leinard, D., Enk, A., Dummer, R., Hantich, B., Geuke, A. M., and Eggermont, A. M. Interferon α-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European organization for research and treatment of cancer melanoma cooperative group. J. Clin. Oncol., 15: 2579-2588, 1997.
27. Schmittel, A., Keilholz, U., Max, R., Thiel, E., and Scheibenbogen, C. Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-α +/-interleukin-2 in patients with metastatic melanoma. Int. J. Cancer, 80: 39-43, 1999.
28. Scheibenbogen, C., Goey, S. H., Proebstle, T., Eggermont, A., and Keilholz, U. Association of increased neopterin levels with response to therapy with CDDP and IFN-α/IL-2 but not with IFN-α/IL-2 alone in melanoma. Anti-Cancer Treatment Sixth International Congress, Abstract 109, 1996.
29. Anderson, C., Buzaid, A., Sussman, J., Lee, J. J., Ali-Osman, P., Braunschweiger, P. G., Plager, C., Bedikian, A., Papadopoulos, N., Eton, O., Legha, S. S., and Grimm, E. A. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res., 8: 149-155, 1998.
30. Buzaid, A. C., Ali-Osman, F., Akande, N., Grimm, E. A., Lee, J. J., Bedikian, A., Eton, O., Papadopoulos, N., Plager, C., Legha, S. S., and Benjamin, R. S. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res., 8: 145-148, 1998.